Company Announcements

In October, Horizon Discovery entered into a coexclusive distribution agreement with Haplogen Genomics, gaining access to cell lines to distribute a new high-throughput, affordable cell line–engineering service.

New England BioLabs signed a supply agreement with TriLink BioTechnologies, for which it will manufacture and supply enzymes for in vitro transcription, capping and poly(A) tailing of RNA.

In October, MIMETAS announced that it raised €5.2 million ($6.6 million) to expand development of its organ-on-a-chip technology.

BioStila, a developer of reagent-based microbial-growth systems, announced a distribution agreement with Sigma-Aldrich.

Tocris, a BioTechne brand, agreed to distribute the Structural Genomics Consortium’s open-access epigenetic chemical probes.

SomaLogic extended its multiyear research agreement with Novartis for its proteomics technology, and Novartis took an equity position in the company.

Eurofins Genomics established a subsidiary in Austria in October through the acquisition of VBC-Biotech’s oligonucleotide-synthesis and DNA sequencing business.

Beckman Coulter Life Sciences launched the DuraClone IM premixed drug reagent cocktails, which are based on collaborative work with the ONE Study consortium. They are designed to streamline and standardize workflow for high-content flow cytometry in translational-research studies.

Clontech Laboratories entered into a license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene-editing system.

Tebu-bio agreed to distribute Spirochrome’s cytoskeleton-staining products in Europe.

Synthetic Genomics named Oliver Fetzer, PhD, MBA as CEO in October. Previously, he was president and CEO of Cerulean Pharma.

AmericanBio and Boval BioSolutions agreed to a joint venture for the development and marketing of Bovine Serum Albumin RNase/DNase Free products.

Lucigen named Board Chairman Ralph Kauten as CEO in October. Former CEO Dr. David Mean continues to serve as CSO.

Product Introductions

PerkinElmer launched in October the AlphaLISA SureFire Ultra assays, designed to reduce assay time and improve the protein phosphorylation-detection process. They use TGR BioSciences’ CaptSure technology.

GE Healthcare Life Sciences introduced the Dharmacon Edit-R Gene Engineering System, utilizing CRISPR-Cas9 gene-engineering technology, which simplifies and accelerates experimental requirements and workflow.